Polycystic Ovary DiseasePharmacologic Treatments for PCOS PatientsKODAMA, SAMANTHA MD, MPH*; TORREALDAY, SAIOA MD, FACOG†Author Information *MedStar Washington Hospital Center, Washington, District of Columbia †Walter Reed National Military Medical Center, Bethesda, Maryland The authors declare that they have nothing to disclose. Correspondence: Samantha Kodama, MD, MPH, MedStar Washington Hospital Center, Washington, DC. E-mail: [email protected] Clinical Obstetrics and Gynecology: March 2021 - Volume 64 - Issue 1 - p 55-64 doi: 10.1097/GRF.0000000000000597 Buy Metrics Abstract Polycystic ovarian syndrome is the most common endocrinopathy in reproductive-aged women and has a vast array of clinical manifestations. Common clinical presentations of the disorder include anovulatory infertility, menstrual disorders, cutaneous symptoms secondary to androgen excess, metabolic abnormalities and mental health issues. If the condition is left unaddressed or inadequately treated, long-term sequelae such as endometrial hyperplasia, diabetes mellitus and dyslipidemia may ensue, therefore it is imperative for clinicians to address each component of the syndrome. When initial lifestyle changes and dietary modifications do not suffice or fail, pharmacologic therapy should be considered, and when deemed appropriate treatment should be initiated. This review describes the pharmacologic options available to combat the various sequelae commonly seen in women with polycystic ovarian syndrome. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.